Study of ARO-INHBE for adults with fatty liver disease
This trial tests an investigational medicine called ARO-INHBE for people with a type of fatty liver disease linked to metabolism. It aims to see if it can improve liver health and may help with weight management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) between 30 and 50, and your weight is 159 kg (about 350 pounds) or less.
- Your weight has been stable recently.
- If you are taking a GLP-1 medicine (like Ozempic or Mounjaro), you must have been on the same dose for at least 6 months.
- If you are not taking a GLP-1 medicine, you either never took one or stopped it at least 6 months ago.
- You do not have severe liver damage, such as cirrhosis or a history of liver-related complications, and you do not have other liver diseases like viral hepatitis or alcoholic liver disease.
- You do not have type 1 diabetes, and your type 2 diabetes is well controlled if you have it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study is testing a new drug that targets thyroid hormone receptors in the liver, alone or combined with another drug, to reduce inflammation and scarring in people with MASH (a type of fatty liver disease). If you have MASH with moderate liver scarring and are otherwise healthy, this trial may help find a new treatment option.
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
This trial tests a new drug, efimosfermin, to see if it is safe and effective for people with cirrhosis caused by MASH (a type of fatty liver disease). It may help improve liver health compared to a placebo.
This study tests an experimental medication called ARO-INHBE in adults with obesity, including those who also have type 2 diabetes. The goal is to see if it helps with weight loss and is safe.
Hear when a new Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.